Posts

Cannabidiol for psychosis: A review of 4 studies

Authors: Sy Atezaz Saeed, MD, MS, and Kathryn E. Clary, BA Published in Current Psychiatry June 2020   Introduction There has been increasing interest in the medicinal use of cannabidiol (CBD) for a wide variety of health conditions. CBD is one of more than 80 chemicals identified in the Cannabis sativa plant, otherwise known as…

Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients.

Authors: Javier Vázquez-Bourgon, Víctor Ortiz-García de la Foz, Irene Suarez-Pereira, et al
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 20 December 2019

INTRODUCTION: Increased incidence of obesity and excess weight lead to an increased incidence of non-alcoholic fatty liver disease (NAFLD). Recent evidence indicates a protective effect of cannabis consumption on weight gain and related metabolic alterations in psychosis patie…

Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials.

Authors: Serena Silvestro, Santa Mammana, Eugenio Cavalli, Placido Bramanti, Emanuela Mazzon
Molecules, April 2019

Cannabidiol (CBD) is one of the cannabinoids with non-psychotropic action, extracted from Cannabis sativa. CBD is a terpenophenol and it has received a great scientific interest thanks to its medical applications. This compound showed efficacy as anti-seizure, antipsychotic, n…

The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.

Authors: Britta Hahn
Schizophrenia Bulletin, 13 January 2018

A major factor associated with poor prognostic outcome after a first psychotic break is cannabis misuse, which is prevalent in schizophrenia and particularly common in individuals with recent-onset psychosis. Behavioral interventions aimed at reducing cannabis use have been un…

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.

Authors: F. M. Leweke, D. Piomelli, F. Pahlisch, D. Muhl, C. W. Gerth, C. Hoyer, J. Klosterkötter, et al
Translational Psychiatry, 20 March 2012

Cannabidiol is a component of marijuana that does not activate cannabinoid receptors, but moderately inhibits the degradation of the endocannabinoid anandamide. We previously reported that an elevation of anandamide levels in cerebrospinal fluid inversely correlated to psychot…

Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia.

Authors: Glenn Schwarcz, Basawaraj Karajgi, Richard McCarthy
Journal of Clinical Psychopharmacology, June 2009

We are reporting improvement of symptoms of schizophrenia in a small group of patients who received the cannabinoid agonist dronabinol (synthetic Delta-9-tetrahydrocannabinol). Before this report, cannabinoids had usually been associated with worsening of psychotic symptoms. I…

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.

Authors: A.W. Zuardi, J.A.S. Crippa, J.E.C. Hallak, F.A. Moreira, F.S. Guimarães
Brazilian journal of medical and biological research, April 2006

A high dose of delta9-tetrahydrocannabinol, the main Cannabis sativa (cannabis) component, induces anxiety and psychotic-like symptoms in healthy volunteers. These effects of delta9-tetrahydrocannabinol are significantly reduced by cannabidiol (CBD), a cannabis constituent whi…